TR201620103A2 - INHALATION FORMULATIONS - Google Patents
INHALATION FORMULATIONS Download PDFInfo
- Publication number
- TR201620103A2 TR201620103A2 TR2016/20103A TR201620103A TR201620103A2 TR 201620103 A2 TR201620103 A2 TR 201620103A2 TR 2016/20103 A TR2016/20103 A TR 2016/20103A TR 201620103 A TR201620103 A TR 201620103A TR 201620103 A2 TR201620103 A2 TR 201620103A2
- Authority
- TR
- Turkey
- Prior art keywords
- pharmaceutically acceptable
- acceptable derivatives
- present
- group
- chronic
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 206010006451 bronchitis Diseases 0.000 abstract 2
- 206010006458 Bronchitis chronic Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010014561 Emphysema Diseases 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000000048 adrenergic agonist Substances 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000007451 chronic bronchitis Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 239000003862 glucocorticoid Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Mevcut buluş; astım, kronik ve akut bronşit, Kronik Obstruktif Akciğer Hastalığı (KOAH), amfizem gibi akciğer hastalıklarının profilaktik ve/veya semptomatik ve/veya terapötik tedavisinde kullanılmak üzere glukokortikoid grubunda yer alan uygun etken madde ve/veya farmasötik olarak kabul edilebilir türevlerinin, uzun etkili selektif ß2-adrenerjik agonistleri grubunda yer alan uygun etken madde ve/veya farmasötik olarak kabul edilebilir türevleri ile kombine tedavisini içeren farmasötik bileşim/ler ile ilgilidir.The present invention includes; suitable active ingredient and / or pharmaceutically acceptable derivatives of the glucocorticoid group for use in the prophylactic and / or symptomatic and / or therapeutic treatment of lung diseases such as asthma, chronic and acute bronchitis, Chronic Obstructive Pulmonary Disease (COPD), emphysema. The present invention relates to a pharmaceutical composition (s) comprising the combined treatment with the appropriate active substance and / or pharmaceutically acceptable derivatives thereof in the group of β2-adrenergic agonists.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR2016/20103A TR201620103A2 (en) | 2016-12-29 | 2016-12-29 | INHALATION FORMULATIONS |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR2016/20103A TR201620103A2 (en) | 2016-12-29 | 2016-12-29 | INHALATION FORMULATIONS |
Publications (1)
Publication Number | Publication Date |
---|---|
TR201620103A2 true TR201620103A2 (en) | 2018-07-23 |
Family
ID=64901710
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2016/20103A TR201620103A2 (en) | 2016-12-29 | 2016-12-29 | INHALATION FORMULATIONS |
Country Status (1)
Country | Link |
---|---|
TR (1) | TR201620103A2 (en) |
-
2016
- 2016-12-29 TR TR2016/20103A patent/TR201620103A2/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1120605T1 (en) | DRY POWDER PREPARATION INCLUDING A PHOSPHODIESTERATION INHIBITOR | |
BR112015006571A2 (en) | pharmaceutical composition, process for preparing a pharmaceutical composition, use of a pharmaceutical composition, and method for the prophylaxis or treatment of asthma, chronic obstructive pulmonary disease and related respiratory disorders | |
MX2019006938A (en) | Methods and compositions for treatment of pulmonary hypertension and other lung disorders. | |
PH12017502087A1 (en) | Tiotropium inhalation solution for nebulization | |
EA201590030A1 (en) | DRY POWDER INHALERS, CONTAINING CARRIER, EXCELLENT FROM LACTOSE, AND THIRD COMPONENT | |
TR201000680A2 (en) | Pharmaceutical compositions containing tiotropium, formoterol and budesonide | |
WO2014016548A3 (en) | Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient | |
TR201000681A2 (en) | Dry powder formulations inhaled. | |
EP2682097A3 (en) | Dry Powder Inhalers Comprising A Carrier Other Than Lactose | |
JOP20200314A1 (en) | Stable pharmaceutical compositions for pressurized metered dose inhalers | |
EA201201397A1 (en) | INHALER CONTAINING DISTRIBUTED GLISTER PACKING | |
MX2022015965A (en) | Combination of alcaftadine and a corticosteroid. | |
EA201401354A1 (en) | NEW DOSED FORM AND PREPARATION CONTAINING ABEDTEROL | |
TR201000622A2 (en) | Pharmaceutical combinations containing tiotropium. | |
EA201201393A1 (en) | INHALER, DEVELOPED FOR DELIVERY OF MEDICINES AS DRY POWDER | |
UA115989C2 (en) | Dry powder inhaler compositions comprising long acting muscorinic antagonists | |
WO2015049519A3 (en) | Method and apparatus for making compositions for pulmonary administration | |
MX368036B (en) | Inhalable particles comprising tiotropium and indacaterol. | |
TR201620103A2 (en) | INHALATION FORMULATIONS | |
MY187442A (en) | A pharmaceutical composition containing budesonide and formoterol | |
BR112017014861A2 (en) | Pharmaceutical combination and composition, dry powder inhaler, use of a pharmaceutical combination, and method for treating a pulmonary disorder. | |
TR201712424A2 (en) | DRY POWDER INHALATION COMPOSITIONS | |
BR112018072177A2 (en) | pharmaceutical composition, container, and methods for treating and preventing nasal congestion, viral respiratory tract infections and / or throat inflammation | |
TR201720846A2 (en) | ORAL PHARMACEUTICAL COMPONENTS | |
EA201201362A1 (en) | PHARMACEUTICAL AEROSOL COMPOSITION PROTEASIS INHIBITORS AND ITS OBTAINING |